Related Experiment Video
Updated: Aug 26, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
A prospective randomized study of two alternating, non cross-resistant chemotherapies for advanced Hodgkin's disease
J P Machiels1, A Ferrant, P Martiat
1Service d'Hématologie, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Bruxelles.
Abstract:
Fifty-four newly diagnosed patients with advanced Hodgkin's disease were randomized between two alternating non cross-resistant chemotherapies: MOPP-ABVD (MOPP: Mustine, Vincristine, Procarbazine, Prednisone-ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine) and MOPP-ABVD-CEM (CEM: Carmustine, Etoposide, methyl-GAG). There were no significant differences between the two therapies as far as complete remission, survival, relapse free survival and toxicity were concerned. This study does not support the use of MOPP-ABVD-CEM for improving the long-term outcome of patients with advanced Hodgkin's disease.
More Related Videos
08:53Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
04:11A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
Published on: June 9, 2026